Discover the latest news, advances, and testimonials from the COMETE project in the first newsletter.
The COMETE project, a transdisciplinary initiative funded by the ERDF (€7.8 million), aims to develop innovative radiopharmaceuticals for the personalized treatment of metastatic and resistant digestive cancers. Led by three partners—Oncodesign Precision Medicine (OPM), ICMUB, and the Centre Georges-François Leclerc (CGFL)—COMETE combines expertise in biopharmacy, molecular chemistry, and nuclear medicine to offer solutions tailored to each patient, combining targeted diagnostic and therapeutic approaches.
In this first edition:
- Principle and benefits of radiotheranostics: A promising approach for targeting and treating cancer cells while limiting side effects.
- Presentation of the consortium: Meet the key players and learn about their roles in the development of these new molecules.
- Latest scientific advances:
- Validation of a stable therapeutic target in pancreatic adenocarcinomas, even at advanced stages.
- Development of bioconjugation strategies to optimize the stability of radiopharmaceuticals.
- Initial in vivo imaging studies to select the most suitable in vivo model.